Cerebrolysin用於急性缺血性中風- Ziganshina | 農藥百科
![Cerebrolysin用於急性缺血性中風- Ziganshina](https://i.imgur.com/WMTbIbA.jpg)
2020年7月14日—ToassessthebenefitsandharmsofCerebrolysinfortreatingacuteischaemicstroke.Searchmethods.WesearchedtheCochraneStrokeGroup ...
![Cerebrolysin用於急性缺血性中風- Ziganshina](https://i.imgur.com/WMTbIbA.jpg)
Effective, simple, and reliable treatment methods are urgently needed to reduce stroke mortality and disability. Many clinical trials and Cochrane Reviews have addressed the question of benefits and risks of potential pharmacological treatment options for acute ischaemic stroke. However, strategies with proven therapeutic effects and an acceptable benefit‐to‐risk ratio are still lacking. Potential strategies can be grouped according to the existing evidence of their benefits and harms determining their role in clinical practice.
Evidence of benefitAspirin at a dose of 160 mg to 300 mg daily (orally or per rectum), started within 48 hours of onset of presumed ischaemic stroke, appears to be the only effective treatment for early secondary prevention, reducing the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications, and improving ...